Junshi Biotech announced the completion of the first patient administration in the phase III clinical trial of JS203 combined chemotherapy for diffuse large B-cell lymphoma.

Zhitongcaijing · 3d ago
Junshi Biotech announced the completion of the first patient administration in the phase III clinical trial of JS203 combined chemotherapy for diffuse large B-cell lymphoma.